On August 21, 2023 Therapeutic Solutions International, Inc. (TSOI) reported that its breast cancer immunotherapy spin-off company, Res Nova Bio, released data showing synergistic suppression of breast cancer growth when used in combination with anti-PD1 and anti-CTLA4 antibodies, which represent clinically used checkpoint inhibitors such as Keytruda and Yervoy, respectively (Press release, Res Nova Bio, AUG 21, 2023, View Source [SID1234634608]). Additionally, the Company demonstrated that FloraStilbene administration increased efficacy of the standard chemotherapies Taxotere and Cytotoxan which are used in breast cancer.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"I have witnessed first-hand the devastating suffering, both mental and physical, that patients with advanced breast cancer go through"
Tweet this
The data were filed in a patent application covering adjuvant use of FloraStilbene in radiotherapy, oncolytic virus therapy, adoptive cellular therapy, chimeric antigen receptor therapy, chemotherapy and immunotherapy.
"I have witnessed first-hand the devastating suffering, both mental and physical, that patients with advanced breast cancer go through," said Dr. James Veltmeyer, Chief Medical Officer of the Company. "The findings announced today are a major accomplishment in our development of non-toxic immunotherapies of breast cancer. By leveraging similarities between pregnancy and cancer we have successfully been able to turn the abortion pill, a drug associated with death, into something that potentially saves lives."
Studies have shown that the abortion pill reduces activity of the cytokine TGF-beta1,2, which is involved in protecting the fetus from the maternal immune response, as well as protecting cancer cells from immunity of the body3. At a cellular level immature dendritic cells, which are found in both cancer and pregnancy seem to be stimulated to maturation by treatment with the abortion pill4.
"I congratulate Ms. Famela Ramos and her team who has already initiated treating advanced breast cancer patients with ValloVax and is now rapidly racing towards the clinic with FloraStilbene," said Timothy Dixon, President, and CEO of Therapeutic Solutions International. "The fact that Res Nova already has secured a manufacturing and distribution partner for FloraStilbene, Cure Stat5 supports our hope of rapidly entering the clinic and perhaps even accelerated sales through a 505b2 mechanism."
"At Res Nova Bio we are fixated on providing hope for patients who currently have very limited hope," said Famela Ramos, President, and CEO of Res Nova Bio. "Knowing the detailed mechanisms of action of our products ensures not only solid intellectual property protection but also respect and credibility of potential acquisition partners and regulators. I am thankful to our scientific team and collaborators for their unceasing dedication to patients and shareholders."